Abstract |
We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma. Pre-RT temozolomide was given for up to 6 cycles. RT with concurrent temozolomide was administered to patients with less than a complete radiographic response. Forty eligible patients were entered and 32 completed protocol treatment. With a median follow-up time of 8.7 years (range 1.1-10.1), median progression-free survival (PFS) is 5.8 years (95 % CI 2.0, NR) and median overall survival (OS) has not been reached (5.9, NR). 1p/19q data are available in 37 cases; 23 tumors had codeletion while 14 tumors had no loss or loss of only 1p or 19q (non-codeleted). In codeleted patients, 9 patients have progressed and 4 have died; neither median PFS nor OS have been reached and two patients who received only pre-RT temozolomide and no RT have remained progression-free for over 7 years. 3-year PFS and 6-year OS are 78 % (95 % CI 61-95 %) and 83 % (95 % CI 67-98 %), respectively. Codeleted patients show a trend towards improved 6-year survival when compared to the codeleted procarbazine/ CCNU/vincristrine (PCV) and RT cohort in RTOG 9402 (67 %, 95 % CI 55-79 %). For non-codeleted patients, median PFS and OS are 1.3 and 5.8 years, respectively. These updated results suggest that the regimen of dose intense, pre-RT temozolomide followed by concurrent RT/ temozolomide has significant activity, particularly in patients with 1p/19q codeleted AOs and MAOs.
|
Authors | Michael A Vogelbaum, Chen Hu, David M Peereboom, David R Macdonald, Caterina Giannini, John H Suh, Robert B Jenkins, Nadia N Laack, David G Brachman, Dennis C Shrieve, Luis Souhami, Minesh P Mehta |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 124
Issue 3
Pg. 413-20
(Sep 2015)
ISSN: 1573-7373 [Electronic] United States |
PMID | 26088460
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Brain Neoplasms
(therapy)
- Dacarbazine
(analogs & derivatives, therapeutic use)
- Female
- Humans
- Longitudinal Studies
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Oligodendroglioma
(therapy)
- Radiotherapy
(methods)
- Retrospective Studies
- Temozolomide
- Tomography, X-Ray Computed
- Treatment Outcome
- Young Adult
|